U.S. Insurance Stock News

Ormat Technologies (ORA) has put fresh expansion plans in focus, outlining investments in geothermal power and energy storage that target 149 MW of added capacity and US$180 million for storage projects, alongside tariff and geopolitical headwinds. See our latest analysis for Ormat Technologies. The expansion plans come as Ormat's share price sits at US$112.84, with a 1 month share price return of 4.67% and a 1 year total shareholder return of 65.96%, indicating strong longer term momentum...

Goldman Sachs recently added Citizens Financial Group (CFG) to its US Conviction List. This move has sharpened investor focus on the bank’s private banking growth, efficiency program, liquidity, and capital returns. See our latest analysis for Citizens Financial Group. CFG’s recent addition to the US Conviction List comes after a period of steady share price momentum, with a 7 day share price return of 5.56% and a 1 year total shareholder return of 84.48% signaling strong recent interest. If...

What triggered Woodward’s latest share move Woodward (WWD) recently rallied after Wells Fargo began covering the stock with a favorable view, along with reports of strong earnings, higher institutional ownership, and recent acquisitions that drew fresh investor attention. See our latest analysis for Woodward. That Wells Fargo coverage and the recent rally sit on top of a stronger trend, with a 90 day share price return of 19.6% and a 1 year total shareholder return of 137.4%, suggesting...

Recent commentary around Onto Innovation (ONTO) centers on strong demand in artificial intelligence and advanced packaging, anchored by a large Dragonfly platform volume agreement with a leading HBM manufacturer that management links to targeted advanced packaging growth. See our latest analysis for Onto Innovation. The recent AI and advanced packaging updates come after a strong run in the shares, with a 30 day share price return of 9.47% and a 90 day share price return of 29.94%, while the...

Arbor Realty Trust (ABR) recently closed a US$762.6m commercial real estate mortgage loan securitization, a financing move that reshapes its funding mix and supports ongoing lending and investment activity. See our latest analysis for Arbor Realty Trust. Despite the fresh securitization and recent preferred dividend declaration, Arbor Realty Trust’s 30 day share price return decline of 12.69% and 1 year total shareholder return decline of 24.33% suggest momentum has softened rather than built...

Why American Homes 4 Rent is back in focus American Homes 4 Rent (AMH) is drawing fresh attention after several research firms reiterated neutral views, pointing to ongoing regulatory pressure and occupancy levels that remain below pre pandemic benchmarks. See our latest analysis for American Homes 4 Rent. The share price has picked up in the very short term, with a 1 day share price return of 3.23% and 7 day share price return of 5.82%. That sits against a 30 day share price return of 3.03%,...

Wendy's (WEN) is back in focus after quarterly results showed US$543 million in revenue that exceeded analyst expectations, but annual EBITDA guidance and same-store sales estimates fell short. See our latest analysis for Wendy's. The mixed earnings reaction fits into a weaker backdrop, with a 30 day share price return of 5.10% and a year to date share price return showing a decline of 15.79%, while the 1 year total shareholder return shows a decline of 45.03% and the 3 year total shareholder...

During March, International Bancshares Corporation’s short interest rose by 24%, climbing from 1,484,699 shares to 1,841,066 shares, marking a clear shift in positioning among traders. This rapid build-up in short positions, occurring even as analyst sentiment remains generally positive, highlights a growing divide between market participants’ expectations. We will examine how this sharp rise in short interest shapes International Bancshares’ investment narrative and what it may signal for...

Event Context and Recent Performance Snapshot Mettler-Toledo International (MTD) recently drew investor attention without a single clear headline event, as its shares closed at US$1,259.94, with a year to date total return of around an 11% decline and a 23.2% gain over the past year. See our latest analysis for Mettler-Toledo International. The recent 7 day share price return of 2.26% contrasts with a 90 day share price decline of 10.73%. However, the 1 year total shareholder return of 23.20%...

Trip.com Group has in the past few months faced an anti-monopoly probe in China over an AI hotel pricing tool, prompting multiple U.S. securities class action filings alleging misleading disclosures about regulatory risks. In response to regulatory scrutiny and partner complaints, Trip.com has shut down the AI pricing system, potentially reshaping how it balances market power with hotel partner relationships and its broader platform economics. We’ll now examine how Trip.com’s regulatory...

Why Cousins Properties is on investors’ radar Cousins Properties (CUZ) has attracted attention after a recent share price pullback, with the stock showing negative returns over the past month and past 3 months despite its established Sun Belt office portfolio. See our latest analysis for Cousins Properties. Over the past year, Cousins Properties has seen a 10.69% decline in total shareholder return, while the recent 7 day share price return of 5.25% hints at short term momentum building from...

Harmonic (HLIT) is back in focus after TDF, a major French broadcast infrastructure operator, upgraded its nationwide terrestrial network using Harmonic’s XOS and ProStream X platforms, spotlighting the company’s media processing capabilities. See our latest analysis for Harmonic. Despite the TDF and KBRO wins and new sports streaming features, Harmonic’s recent momentum has been mixed, with a 30 day share price return of a 7.35% decline contrasting with a 1 year total shareholder return of...

Artivion’s recent Q4 results showed revenue rising 19.2% year on year, driven by strong growth in stent grafts, On-X products, and preservation services, but coming in just 0.8% below analyst expectations. Despite delivering solid full-year 2025 adjusted revenue and EBITDA growth, Artivion’s relatively weaker performance versus peer estimates raises questions about how much near-term momentum investors should expect. Next, we’ll examine how this slight quarterly revenue miss, despite strong...

In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint. The brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab. We’ll now examine how the...

In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label. These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...

Recent comments from television host Jim Cramer, who questioned Western Union (WU) as a growth idea despite its dividend appeal, have put the stock back in focus after a roughly 6.5% move higher. See our latest analysis for Western Union. The recent 6.5% share price move and 1 day share price return of 2.96% come against a weaker backdrop, with a 30 day share price return of 10.21% and a 1 year total shareholder return of 4.4% and 5 year total shareholder return of 49.31%. This suggests...

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its first GAAP profitability, and completing enrollment in several key clinical trials. See our latest analysis for Mirum Pharmaceuticals. The recent clinical and regulatory milestones appear to have fed into strong momentum, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 124.05%. The current share price...

In March 2026, FTI Consulting, Inc. appointed Kelly Henney as Senior Managing Director and Australia Leader of its Information Governance, Privacy & Security practice within the Technology segment, based in Sydney. Her background in artificial intelligence governance, data privacy, and digital risk, combined with legal and banking experience, enhances FTI’s ability to advise clients on complex regulatory and compliance challenges. Next, we’ll examine how Henney’s artificial intelligence...

In March 2026, Flex LNG Ltd. announced a new time charter for the Flex Aurora with a Supermajor, securing a firm two-year term plus optional extensions that could keep the vessel employed through 2034 and lift the company’s total contract backlog to a minimum of 55 years, or up to 82 years if all options are used. This incremental charter backlog adds further revenue visibility at a time when the company has flagged potential revisions to its full-year 2026 guidance amid volatile LNG...

On March 18, 2026, Core Scientific, Inc. entered into an amendment to its Delayed-Draw Bridge Credit Agreement, increasing total term loan commitments by US$500.0 million to US$1.0 billion and drawing the full incremental amount on the closing date. This substantial expansion of borrowing capacity materially alters Core Scientific’s financial flexibility, potentially affecting how it funds high‑performance computing projects and manages its evolving capital structure. We’ll now examine how...

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...

In late March 2026, investors reacted to easing geopolitical tensions and a broader relief rally as confidence improved around NextNav’s prospects for an FCC Notice of Proposed Rulemaking tied to its 5G-based terrestrial GPS backup system. This shift in sentiment highlights how progress toward a clearer regulatory path can become a central driver of interest in NextNav’s spectrum-backed positioning and timing platform. Now we’ll examine how growing optimism around the FCC regulatory...

Oil driven pullback puts BKV in focus The recent easing of U.S. Iran tensions pushed oil prices lower, dragging energy names with them as traders locked in gains after a strong run and technical gauges flagged oversold conditions across the sector. BKV (BKV) was caught in that macro driven move, with selling pressure tied less to company specific headlines and more to shifting sentiment toward oil and gas exposure in the short term. See our latest analysis for BKV. That macro volatility sits...

On March 30, 2026, Option Care Health expanded its revolving credit facility by US$450 million to US$850 million and increased its share repurchase authorization to US$1 billion, while reaffirming its 2026 guidance. The move strengthens liquidity and signals management’s confidence in cash generation, giving the company more flexibility to fund growth and return capital to shareholders. We’ll now examine how the expanded US$1 billion buyback authorization reshapes Option Care Health’s...